E ndothelial cells (ECs) lining capillaries of different organs have specialized gene expression patterns, morphologies, and functions related to the specific needs of tissue parenchymal cells with which they communicate.
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and cardiomyocytes may also play a role in these pathologies. [13] [14] [15] [16] [17] [18] [19] [20] [21] Nevertheless, it has not been established whether cardiac ECs are specialized to fulfill the high FA delivery demanded by the heart. Recent studies identified vascular endothelial growth factor (VEGF)-B as a paracrine mediator of FA uptake through ECs in the heart, brown adipose tissue, and skeletal muscle and showed that VEGF-B inhibition protected against type 2 diabetes mellitus by decreasing FA uptake and reverting muscle metabolism toward glucose consumption. 21, 22 However, EC-intrinsic (transcriptional) regulators determining FA uptake and transfer are unknown, with the exception of peroxisome proliferator-activated receptor (PPAR) γ, whose activities are not restricted to the heart. 23 We identified 2 novel transcriptional regulators of the gene signature and metabolic substrate transport in heart ECs, that is, Meox2 and Tcf15. They both have been described to play a role in the specification of paraxial mesoderm to somitic dermomyotome, and a defect in heart development has not been reported in Meox2-or Tcf15-deficient mice. [24] [25] [26] Meox2 participates in EC homeostasis, 27, 28 whereas Tcf15 has never been studied in ECs, except that it was cloned from an endothelial library. 29 Here, we demonstrate that, within the adult heart, Meox2 and Tcf15 are exclusively expressed in ECs, and that they are critical regulators of FA transport across cardiac ECs.
Methods
An extended Methods text is available online, which includes Table  I in the online-only Data Supplement (antibodies) and Table II in the online-only Data Supplement (quantitative real-time polymerase chain reaction primers).
Animal/Human Biopsies
ECs for expression profiling were sorted from Tie2-GFP mice.
Meox2
Cre/+ mice (referred to as Meox2 +/-; C57Bl/6) were obtained from the Jackson Laboratories and Tcf15 +/-mice (129S7/ SvEvBrd*C57Bl/6) were provided by E. N. Olson/A. Rawls (Dallas, TX/Tempe, AZ). 24 Human biopsies obtained under informed consent were handled according to the Helsinki Declaration. Procedures were approved by the Ethics Committees of KULeuven for Animal Use, or University Hospitals Leuven.
Cell Isolation/Culture
ECs were sorted by fluorescence-activated cell sorting based on Tie2-GFP fluorescence or antibodies, or selected with antibodyconjugated magnetic beads. Cells were collected in RNA extraction buffer or collection buffer for protein extraction or FA-uptake experiments. Cardiomyocytes were isolated by using a Langendorff perfusion setup. For in vitro studies, human heart ECs and human umbilical vein ECs were grown in EBM2 medium supplemented with EGM2-MV bullet-kit on gelatin-coated plates, and cardiomyocytes were plated on laminin-coated dishes in protein-supplemented M199 medium.
Microarray
Mouse genomewide microarrays on ECs were performed by the VIB Nucleomics Core, as described in the online-only Data Supplement. Functional annotation analysis was done on the validated heart EC gene list with the use of DAVID software (http://david.abcc.ncifcrf. gov/).
RNA/Protein/cDNA Preparation, Quantitative Real-Time Polymerase Chain Reaction, Western Blot, Enzyme-Linked Immunosorbent Assay, and Enzymatic Activity Assays
Total RNA was extracted with RLT or TRIzol, retrotranscribed using SuperscriptIII Reverse Transcriptase, and quantitative real-time polymerase chain reaction was performed with SYBR-Green master mix. For Western blot, total proteins were extracted with radioimmunoprecipitation assay buffer containing protease inhibitors. Human apolipoprotein B and mouse lipoprotein lipase (Lpl) protein were measured by enzyme-linked immunosorbent assay, and Lpl activity was measured with a colorimetric kit.
Lentiviral Overexpression/siRNA Knockdown
The construct for overexpressing human MEOX2 was purchased (Genecopoeia). Open reading frames for human WT1, EBF3, and murine Tcf15 were cloned from cDNA-containing plasmids (Thermo Scientific), and PPARG1 (further referred to as PPARG) was cloned from human heart EC cDNA. Lentiviruses were produced in HEK293 cells. Lentiviral transduction, lysate harvesting, and siRNA knockdown of CD36 or LPL were performed as described in the onlineonly Data Supplement.
Proximity Ligation Assay/GST Pull-Down Assays
Proximity ligation assay was performed as previously described 30 in human umbilical vein ECs overexpressing MEOX2 and FLAGtagged Tcf15 or PROX1. Glutathione S-transferase (GST) pull-down assays were performed in HEK293 cells transfected with plasmids encoding GST-tagged Tcf15, FLAG-tagged MEOX2, or both.
In Vitro/Ex Vivo FA Uptake/Transport FA uptake was analyzed as described in the online-only Data Supplement in cultured human heart ECs 72 hours posttransduction or after siRNA treatment, in freshly isolated magnetically selected murine heart ECs or in adult murine cardiomyocytes, 4 hours after plating. FA transport in EC mono-or coculture with cardiomyocytes was analyzed as described in the online-only Data Supplement.
Histology
Immunofluorescence and Sirius red staining were performed on 3-to 6-μm paraffin sections. Oil Red O staining was performed on 10-μm cryosections as described in the online-only Data Supplement.
Echocardiography
Mice (n=8-9; analyzed at 3-4 and 11 months of age) were sedated with 1.5% isoflurane and standard views were obtained in 2 dimensions by transthoracic echocardiography by using an MS400 transducer on a Vevo2100 scanner. Image analysis was performed by a blinded investigator using VisualSonics software.
FA/Glucose Uptake
For FA uptake assessment in vivo, mice were injected intravenously with 14 C-oleic acid (OA) or [ 3 H]OA, and, after 30 minutes, radioactivity in different organs/plasma was measured on an LKB-WallacRackbeta-1214 Counter or hearts were harvested and processed for semithin sectioning and autoradiography. Glucose uptake was determined by positron emission tomography imaging during 1 hour after intravenous injection of 2-deoxy-2-[ Figure 1 . The heart EC fingerprint is enriched in lipid transport-related genes. A, Principal component diagram and heat map from a microarray on freshly isolated ECs from murine (m) heart, brain, and liver (n=5). B, Log 2 probe set intensity of validated genes from the heart EC fingerprint in murine heart, liver, and brain ECs (n=5;*P<0.05 vs heart ECs). C, Functional annotation of significantly enriched gene categories from the heart EC fingerprint. D, mRNA expression (qRT-PCR) of heart EC fingerprint genes in SkM, BAT, or WAT relative to heart ECs (n=3-4;*P<0.05 vs heart ECs and a minimum 4-fold difference). E, Western blots of Meox2, Tcf15, housekeeping protein expression (α-Tubulin/Gapdh), or loading control (Ponceau) in sorted ECs and non-ECs from the heart or freshly isolated cardiomyocytes. F, Immunofluorescence stainings for Meox2 or Tcf15 (red; white arrowheads) in murine heart, liver, and brain tissue (ECs stained by lectin in green; arrows indicate EC nuclei 
Results
Gene Signature of Heart Capillary ECs
To obtain a heart microvascular EC signature, we performed a microarray comparison of pure populations of GFP + ECs freshly isolated from the hearts, livers, and brains of adult Tie2-GFP mice (Figure IA through IC and Note I in the online-only Data Supplement) revealing a high degree of heterogeneity between vascular beds ( Figure 1A ). After filtration (by defining as a threshold a minimum Log 2 probe set intensity of 6 and a minimum 4-fold difference in comparison with brain and liver ECs [P<0.05]) and quantitative real-time polymerase chain reaction validation of the gene list (only genes significantly enriched in the EC fraction in comparison with non-ECs and/or cardiomyocytes were retained [P<0.05], data not shown), we obtained a set of 31 genes enriched in heart capillary ECs ( Figure 1B ). Functional annotation revealed that the main functions represented were lipid binding and lipid/ FA transport ( Figure 1C ). To consolidate this signature, we measured its expression in ECs freshly isolated from additional tissues, ie, pancreas, lung, and kidney. We found that most genes (81% in comparison with at least 2 tissues, 48% in comparison with all 3 tissues) were at least 4-fold enriched in heart ECs ( Figure ID in the online-only Data Supplement). On the other hand, ECs isolated from tissues with continuous endothelium that, like the heart, are highly active in FA uptake for energy production or storage (ie, skeletal muscle or SkM, brown and white adipose tissue or BAT and WAT, respectively) showed for most genes an expression level similar to that in heart ECs ( Figure 1D ). Cross-species validation in human ECs confirmed a partially retained enrichment of the signature in human heart in comparison with brain and liver ECs ( Figure IIA in the online-only Data Supplement). Finally, as for other EC types, 2,31,32 human heart ECs lost their specific gene expression profile upon culturing ( Figure IIB in the online-only Data Supplement).
Transcriptional Regulation of Heart EC Identity In Vitro
In addition to FA transport-related genes, the signature contained 5 TF-encoding genes, ie, Meox2, Tcf15, early B-cell factor 3 (Ebf3), Pparg and Wilms tumor 1 (Wt1; Figure 1B ). We confirmed by tissue immunostaining and Western blot on sorted cells that Meox2 and Tcf15 were exclusively expressed in the EC compartment of the murine heart and undetectable in liver or brain ECs ( Figure 1E and 1F and Figure III in the online-only Data Supplement). We next tested whether these TFs would intrinsically regulate the heart EC signature by assessing whether their overexpression would restore the fingerprint in human heart ECs in which it was erased by culturing. Overexpressing MEOX2 or Tcf15 alone did not affect signature gene expression; however, when overexpressed in combination, 31% of the genes were significantly upregulated ( Figure 2A ). Proximity ligation assay and GST pull-down revealed that this cooperative effect involved heterodimeric complex formation ( Figure 2B and 2C) . MEOX2 or Tcf15 did neither affect each other's expression nor that of WT1, but had a small yet significant inductive effect on PPARG. EBF3 was strongly induced by MEOX2+Tcf15. Yet, its overexpression induced a limited number of signature genes and thus did not recapitulate the effect of MEOX2+Tcf15. Furthermore, combining EBF3 overexpression with MEOX2+Tcf15 did not have an additive effect ( Figure IVA in the online-only Data Supplement). We also studied the inductive effect of PPARG and the most abundant WT1 isoform (Note II in the online-only Data Supplement). PPARG and WT1 overexpression partially induced the heart EC fingerprint ( Figure IVB and IVC in the online-only Data Supplement). Moreover, PPARG exerted a synergistic effect with MEOX2+Tcf15, whereas WT1 did not have an additive effect on MEOX2+Tcf15+PPARG overexpression. Upregulation for a random gene subset was confirmed at protein level ( Figure IVD in the online-only Data Supplement). MEOX2+Tcf15 overexpression induced the heart EC signature in human umbilical vein ECs to a similar extent as in cultured heart ECs ( Figure IVE in the online-only Data Supplement).
Meox2/Tcf15 Determine Heart EC Identity In Vivo
To address whether Meox2 and Tcf15 cooperated to affect the heart EC expression profile in vivo, mice lacking 1 allele of each factor were generated. Mice homozygously deficient for Tcf15 (24) Figure 3A ). Complementary to our in vitro findings, Pparg and Ebf3 were significantly downregulated, whereas Wt1 was not affected, confirming the TF hierarchy we unraveled in vitro (Figure 2A ). General EC markers were not affected in heart ECs, and liver sinusoidal EC-specific genes were not altered in liver ECs ( Figure  VA and VB in the online-only Data Supplement), suggesting that Meox2/Tcf15 specialize ECs in the heart, while neither affecting EC identity per se, nor EC specialization in unrelated tissues.
Meox2+Tcf15 Haplodeficiency Alters Energy Substrate Transporter Gene Expression in Heart ECs In Vivo
Because FA transport emerged as a principal function associated with the heart EC signature, we further investigated whether Meox2+Tcf15 haplodeficiency altered endothelial expression of additional genes encoding FA or glucose transport-related Figure 3B and 3C) . Expression of Fatp4, another FA transporter gene induced by VEGF-B, 21 was not affected by Meox2+Tcf15 haplodeficiency ( Figure 3C ). Reduced CD36 expression in Meox2
+/-heart ECs was confirmed at the protein level ( Figure 3D ). Together, these observations further suggest a functional role for Meox2+Tcf15 in FA (and glucose) transfer in and through heart ECs.
Meox2/Tcf15 Drive Free FA Uptake in and Transport Across ECs
To demonstrate that Meox2/Tcf15 are functionally important for FA trafficking, we next determined whether free FA (FFA) uptake in cultured human heart ECs could be enhanced by their overexpression. As measured by fluorescence-activated cell sorting, uptake of bovine serum albumin-bound fluorescently labeled dodecanoic acid was increased by 150% upon MEOX2+Tcf15 overexpression ( Figure 4A) Figure 3B and 3D) , whereas it was upregulated upon combined MEOX2+Tcf15 overexpression in cultured heart ECs and human umbilical vein ECs (unlike other transporters; Figure VIA and VIB in the online-only Data Supplement and data not shown), and because CD36 is the FA transporter expressed at the highest level in heart ECs (>200-fold higher than any other FA transporter; Figure VIC in the onlineonly Data Supplement), we investigated whether CD36 was involved in Meox2/Tcf15-driven FFA uptake. CD36 knockdown reduced FFA uptake by 12% in heart ECs overexpressing MEOX2+Tcf15, meaning that CD36 accounted for ≈20% of the uptake caused by combined MEOX2+Tcf15 overexpression ( Figure 4C ). Using an in vitro transwell assay, we deliver proof that Meox2/Tcf15 also affected FFA transport Figure 4D ). Finally, with a coculture system we showed that Meox2/Tcf15 regulate the capacity of ECs to take up and transfer FFAs to cardiomyocytes ( Figure 4E ).
Meox2/Tcf15 Regulate VLDL-Derived FA Uptake in Heart ECs
FAs reach the heart EC barrier not only bound to albumin (FFAs) but also esterified in the triacylglycerol core of circulating lipoproteins (eg, chylomicrons or very-low-density lipoproteins [VLDL]). We determined whether Meox2/Tcf15 could regulate VLDL-derived FA uptake by measuring the uptake of 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate (DiI) signal incorporated in the lipidic parts of DiIlabeled VLDL. MEOX2+Tcf15 overexpression in cultured heart ECs induced an increase of DiI uptake by 53% ( Figure 5A) , and, accordingly, in heart ECs freshly isolated from Meox2 +/-:Tcf15 +/-mice, DiI uptake was decreased by 22% in comparison with wild-type mice ( Figure 5B ). It is known that in vivo, triglyceride-derived FAs from VLDL can be taken up by tissues either as a component of nascent or remnant lipoprotein particles or as FFAs following Lpl-mediated triglyceride lipolysis at the luminal EC surface. [34] [35] [36] In our in vitro system, VLDL particle uptake occurred and MEOX2+Tcf15 overexpression tended to increase this, as shown by the uptake of Apolipoprotein B protein, but this increase was not significant (Figure VIIA in the online-only Data Supplement). On the other hand, we found Lpl mRNA expression in pure heart ECs ( Figure 1B) , the levels of which were 25% of those in pure cardiomyocytes ( Figure 5C ). Because, in comparison with wild-type, Meox2
+/-hearts show a downregulation of Lpl mRNA by 90% in their EC but not cardiomyocyte fraction ( Figure 3A and Figure VIIIA in the online-only Data Supplement) and had an ≈18% decrease in Lpl protein and activity ( Figure 5D and 5E), we estimated that EC-derived Lpl activity is ≈20% of that in the total heart. Furthermore, MEOX2+Tcf15 overexpression in cultured heart ECs increased lipoprotein lipase (LPL) activity by 48%, and this increase was completely neutralized upon LPL knockdown ( Figure 5F ). Together, these results support the production of active Lpl by heart ECs and its regulation by Meox2/Tcf15. To demonstrate that this EC-produced LPL-hydrolyzing activity was involved in MEOX2+Tcf15-driven VLDL-derived FFA uptake, we knocked down CD36, an important downstream mediator of LPL-generated FFAs that is not involved in VLDL particle uptake 35 ( Figure VIIB in the online-only Data Supplement). CD36 knockdown in MEOX2+Tcf15-overexpressing heart ECs decreased the DiI signal by 13% ( Figure 5G ). Together, these data demonstrate an EC-autonomous role for Meox2/Tcf15-regulated Lpl in VLDL-derived FFA uptake.
Meox2/Tcf15 Regulates Cardiac Energy Substrate Uptake In Vivo
To evaluate whether Meox2+Tcf15 haplodeficiency altered FA uptake in the heart in vivo, we administered 14 C-OA via tail vein injection to 12-to 16-week-old Meox2
+/-and wild-type males, and measured the radioactive signal in different organs after 30 minutes. FA uptake was significantly decreased in the heart (by 35%), and was also decreased (by 50%) in oxidative SkM (soleus) in Meox2
+/-mice -as expected by the fact that Meox2 and Tcf15 are also expressed in the SkM endothelium, which also expresses the other genes of the heart EC signature at high levels ( Figure 6A ). Unexpectedly, however, FA uptake was significantly increased (by ≈100%) in BAT of Meox2
mice, although BAT ECs had similar levels of expression of the genes of the heart EC fingerprint and FA transporters than heart ECs, and showed downregulation of, eg, CD36 and Lpl in Meox2
+/-mice ( Figure 1D and Figure IXA and IXB in the online-only Data Supplement). Other organs had a similar uptake in the 2 genotypes. Although we detected a 22% increase in radioactive signal in plasma of Meox2 +/-mice displayed heart systolic dysfunction, as evidenced by a reduced ejection fraction and fractional shortening, sporadically accompanied by fibrosis and associated with a slight decrease in capillary density, but no significant differences in cardiomyocyte size ( Figure 7 and Tables III and IV in the online-only Data Supplement).
Discussion
To improve the understanding of EC heterogeneity between capillaries of different organs, we here report a fingerprint of genes enriched in heart microvascular ECs, which is largely shared with ECs of SkM, BAT, and WAT, all tissues highly active in FA uptake for energy production or storage. We show that Meox2 and Tcf15, by interacting as a heterodimeric complex, EC-autonomously determine the expression of these fingerprint genes both in vitro and in vivo, while individually they had only a minor effect.
Our in vitro and ex vivo mechanistic studies showed that Meox2/Tcf15 intrinsically regulate uptake by cardiac ECs of FFAs originating from both bovine serum albumin conjugates and EC-derived Lpl hydrolysis of triglycerides contained in VLDL particles (Figure 8 ). Although the finding of EC-derived Lpl challenges the currently prevailing view that cardiomyocytes are the sole cardiac source of Lpl, 34 we estimated that EC-derived Lpl protein and activity is ≈20% of that in the whole heart, which is well in line with the observation by Bharadwaj et al 35 that there is ≈14% residual Lpl activity in hearts of cardiomyocyte-specific Lpl-deficient mice. Meox2/Tcf15 also potentially regulate the expression of Gpihbp1, 34 responsible for Lpl transfer from cardiomyocytes and for its positioning at the luminal surface of heart capillary ECs (Figure 8 ). Using a combination of gain-and loss-of-function experiments, we showed that CD36 is downstream of Meox2/Tcf15-mediated uptake of FFAs originating from both bovine serum albumin conjugates and VLDL particles in heart ECs. The high CD36 expression levels in comparison with other transporter genes in heart ECs further support its important role in cardiac FA uptake. Nevertheless, although, in our DiI-VLDL assay, CD36's contribution to Meox2/Tcf15-driven FFA uptake could have been underestimated by simultaneous detection of particle uptake, the fact that CD36 knockdown only partially impaired Meox2/Tcf15-driven uptake of BODIPY-labeled FFAs suggests the existence of other Meox2/Tcf15 downstream mediators or the occurrence of compensatory mechanisms upon CD36 knockdown.
In Meox2 +/-:Tcf15 +/-heart ECs, Fatp3, a FA transporter regulated by the paracrine VEGF-B, 21 was increased, but this was not sufficient to fully compensate for the partial loss of CD36 induced by Meox2+Tcf15 haplodeficiency, because cardiac FA uptake was significantly compromised in the Meox2 +/-:Tcf15 +/-heart. On the other hand, Fatp4, another FA transporter regulated by VEGF-B, 21 was not affected by the haploinsufficiency of Meox2+Tcf15 in heart ECs. Finally, MEOX2+Tcf15 overexpression did not regulate FATP3 or FATP4 in vitro (data not shown), whereas VEGF-B is not able to regulate CD36. 21 Therefore, we hypothesize that these extrinsic and intrinsic pathways do not overlap in regulating FA uptake in heart ECs. On the other hand, we found that Pparg, known to be an intrinsic regulator of EC FA uptake, 23 seemed to be downstream of and synergize with Meox2/Tcf15 to determine the heart EC signature, suggesting a new TF hierarchy in charge of endothelial FA uptake.
Meox2/Tcf15 did not only support FA uptake in, but also transport across ECs, as shown with a transwell assay. In particular, they could regulate the capacity of ECs to take up and transfer FAs to cardiomyocytes, as shown in our in vitro coculture experiments. Meox2/Tcf15-mediated transendothelial transport was likely dependent on CD36-mediated FA uptake and may involve certain fingerprint genes and cytoplasmic FA transporters in charge of FA shuttling from the apical to the basal side of ECs, such as Fabp4 and Fabp5, the loss of which is known to decrease FA uptake in the heart 33 and which were downregulated in heart ECs of Meox2
+/-mice ( Figure 8 ).
In vivo, Meox2+Tcf15 haplodeficiency caused decreased FFA uptake in the heart. Surprisingly, despite a similar expression of signature genes and FA transporters in heart and BAT ECs and a common downregulation of CD36 In summary, here we provide for the first time a fingerprint of genes enriched in ECs lining capillaries of tissues with high metabolic capacity for FAs, suggesting a common specialization of these vascular beds. We identified Meox2/Tcf15 heterodimers as transcriptional determinants of the heart EC fingerprint and demonstrated that they are critical regulators of FA transport across heart ECs, in part, through the regulation of CD36 and Lpl expression. Combined Meox2+Tcf15 haplodeficiency resulted in downregulation of these and other FA transport-related genes and an increase of glucose transporter Glut1 in heart ECs, and a switch of the cardiac energy substrate balance (Figure 8 ). These findings have broadened our understanding of the genetic identity and physiological role of heart microvascular endothelium and provide a platform for further mechanistic studies for therapeutic exploitation of specific EC targeting aimed at modulating the energy substrate uptake in the heart or promoting heart-specific revascularization. 
CLINICAL PERSPECTIVE
Endothelial cells lining capillaries of different organs have specialized gene expression patterns, morphologies, and functions in relation to the specific needs of the tissue parenchymal cells with which they communicate. This microvascular endothelial heterogeneity is determined by environmental cues and intrinsic regulators (eg, transcription factors), many of which remain largely unknown. Furthermore, unlike for liver or brain, information on the specific characteristics of endothelial cells in the heart is currently lacking. Understanding these characteristics and the mechanisms that determine them may form the basis of new therapeutic strategies to tackle heart disease. Here, we identified Meox2 and Tcf15 as transcriptional codeterminants of the heart endothelial gene signature that program the heart endothelium for fatty acid uptake and transport to the heart parenchyma. Combined heterozygous deficiency for these transcription factors resulted in reduced fatty acid uptake and a compensatory increase in glucose uptake in the heart. Because there are many forms of cardiac dysfunction related to changes in energy substrate usage, our insights could be used to develop new strategies based on endothelial Meox2/Tcf15 targeting to treat such dysfunction.
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SUPPLEMENTAL MATERIAL I. EXPANDED METHODS AND RESULTS
A. Extended Methods
Animals and human biopsies. Tie2-GFP mice 1 were used as EC donors for expression profiling. -fraction was sorted and re-plated ('passage (P)1') and propagated up to P10. Cells between P1-10 were used for expression profiling of the heart EC signature by qRT-PCR or for lentiviral transduction of heart EC transcription factors (TFs) as described below. Before every experiment cell purity was assessed by CD31 FACS staining. HUVECs were isolated as described 3 For validation, only genes with an absolute Log 2 probe set intensity≥6 and presenting a minimal difference between tissues of 2 Log 2 probe set intensity (corresponding to a 4-fold or higher difference; Perkin Elmer) in Gey's buffer + 0.1% FA-free BSA. Thereafter, HUVEC monolayers were extensively washed (5 times for 2-3 minutes) with Gey's buffer and the transwell column was transferred to a 24-well plate containing primary rat cardiomyocytes (Lonza). The co-culture was incubated in cardiomyocyte medium (Lonza) for 6 hours at 37ºC to allow the transfer of 14 C-OA from ECs to the cardiomyocytes. Next, the transwell column was removed and cardiomyocytes were thoroughly washed with PBS containing Ca 2+ and Mg 2+ (3 times for 2 minutes) and lysed with PBS + 1% Triton 7 for 5 minutes. Cell lysates were resuspended in Emulsifier Safe Liquid Scintillation Cocktail (PerkinElmer) and total radioactivity was measured by liquid scintillation counting.
Meox2
P<0.05) were retained. Microarray data is accessible at the NCBI Gene Expression Omnibus website
LPL protein and activity quantification. For quantification on tissues, whole hearts were isolated from Meox2 +/-:Tcf15 +/-and wild-type mice anesthetized by i.p. injection of a ketamine (100 mg/kg) and xylazine (10 mg/kg) mixture and perfused through the heart apex with 0.9% saline solution to completely remove the blood. Hearts were snap-frozen in liquid N 2 and stored at -80°C until analysis.
Frozen hearts were homogenized by shaking (using a Ribolyser) in 300 μl of PBS containing protease inhibitors and lysing matrix D (MP Biomedicals). Cleared supernatants were used for protein quantification and for LPL ELISA (Cusabio) and LPL activity measurement (Roar) according to the manufacturer's instructions. For quantification of LPL activity on cultured cells, cell monolayers were thoroughly washed in PBS, trypsinized, washed again in PBS and collected in 100 μl PBS containing protease inhibitors. LPL quantity and activity were normalized for protein content.
Proximity ligation assay (PLA)
. PLA was performed using the DuolinkII PLA kit (Sigma) as GST pull-down assay. GST pull-down assay was performed according to the manufacturer's instructions with minor modifications (Pierce GST Protein Interaction Pull Down Kit). Two 10 cm 2 plates were seeded with 5x10 6 HEK293 cells each and transfected with 4 μg of GST-Tcf15 and 4 μg of FLAG-MEOX2 plasmids alone or in combination. When GST-Tcf15 and FLAG-tagged MEOX2 were used alone, 4 μg of Cherry control plasmid was also added. Forty-eight hours after transfection, cells were collected, lysed and incubated on glutathione agarose columns overnight. The next day, unbound proteins were extensively washed, followed by elution of bound proteins with 100 mM glutathione.
Protein interactions were analyzed by Western blot using anti-GST and anti-FLAG antibodies (Supplementary Table I ).
Histology. Sirius-red, immunofluorescence and Oil Red-O stainings were performed as described 5, 6 .
Briefly, for Oil Red-O staining, mice were anesthetized with pentobarbital, hearts were rapidly excised, washed in KCl 1M and PBS, directly snap-frozen in liquid N 2 and conserved at -80°C until used.
Frozen hearts were embedded in Tissue-tek freezing medium (Leica Biosystems), cryo-sectioned at 10 µm, air-dried for 10 minutes and immediately stored at -20°C to be used the same day. Tissues were rinsed with milliQ water and fixed for 1 hour with 3.7% formaldehyde in milliQ water. After one rinse in milliQ water, slides were immersed in a freshly prepared, Wattman-filtered Oil Red-O solution weighed and solubilized by the addition of Solvable (PerkinElmer, 1 ml/100 mg tissue) in a glass scintillation vial and incubated at 60°C overnight. After cooling to room temperature, 30% (w/w) hydrogen peroxide was added followed by heating at 60°C for another hour to minimize color quenching of samples. Finally, scintillation fluid (Normascint, Scharlab) was added to each sample followed by vigorous shaking. The vials were then allowed to equilibrate in the dark for at least 60 minutes before scintillation counting using an LKB-Wallac-Rackbeta-1214 Counter (PerkinElmer). was injected through the tail vein simultaneously at the beginning of a list mode study of 60 minutes.
For each study, a summed sinogram of the whole emission study and an 18 frame dynamic sinogram (2 ×15"; 7×30"; 1×60"; 1x120"; 1x180"; 2x300"; 4x300") were created. From these sinograms, both a summed and a dynamic image were generated containing the information about the corresponding time intervals. All the images were reconstructed using the 3D Ramla algorithm with 2 iterations and a relaxation parameter of 0.024 into a 128×128 matrix with a 1 mm voxel size applying dead time, decay, random and scattering corrections. For the assessment of [ 18 F]FDG uptake in the heart, all studies were exported and analyzed using the PMOD software (PMOD Technologies Ltd., Adliswil, Switzerland).
For each mouse, a volume of interest (VOI) of the heart was drawn on coronal 1 mm-thick slices of summed PET images. Then, VOI was applied to the dynamic image to obtain the [ 
B. Supplementary Notes
Supplementary Note I. Microvascular EC purity.
As a source for sorting ECs from the heart, we used Tie2-GFP mice in which the Tie2 promoterenhancer is active in blood-vascular but not lymphatic ECs 1 . As previously described, CD36 is highly expressed in microvascular ECs and absent in ECs from large vessels 7 . Nevertheless, between capillary
ECs from different organs there is a different degree of expression of CD36, being very low in brain
ECs and high in liver and heart ECs (ref. 8 and as evident from our microarray analysis; Supplementary Figure VC) . Indeed, for heart and liver, microvascular EC purity could be determined by FACS for CD36 (as shown for the heart in Supplementary Figure IA) , whereas under identical FACS staining conditions we could not detect CD36 positive cells in brain ECs. Therefore, to confirm microvascular EC purity of brain EC preparations, we relied upon the significant enrichment for known brain-specific microvascular EC markers such as Glut1, Lat1, Ocln and Tfrc (Supplementary Figure IC) .
Supplementary Note II. Relative abundance of WT1 isoforms in cardiac ECs.
Several WT1 isoforms have been described with different tissue specificities and functions 9 . We quantified the relative abundance of the long versus short isoforms (the latter generated from an alternative start codon in intron 1) and of the isoforms carrying or not the KTS domain in freshly isolated human and mouse heart ECs and found that the most abundant WT1 isoform in heart ECs is the isoform expressing exon1 and the KTS domain (ratio isoform -exon1/isoform + exon1 = 1:1,500, and 71 ± 8% carrying the KTS element). We therefore overexpressed the isoform D (expressing exon1, exon5 and carrying KTS), the most prevalent isoform of WT1 (9) in normal tissues, to test its effect on the heart EC gene signature. A, Representative FACS plots of heart homogenates from Tie2-GFP mice showing gate (G1) setting for sorting of GFP + endothelial cells (ECs) and G1 analysis revealing 99% purity for EC marker CD31
and 96% for microvascular EC marker CD36 (7) , and negligible contamination (<1%) with hematopoietic cells (expressing CD45). B, Probe set intensities for heart, brain and liver EC samples for vascular endothelial, lymphatic endothelial, pericyte-smooth muscle or hematopoietic markers demonstrating the purity of the sorted EC fractions used for microarray. C, Probe set intensities for heart, brain and liver EC samples for previously described heart, brain and liver-specific microvascular EC markers, demonstrating the expected enrichment of previously known tissue-specific microvascular EC markers in the corresponding tissue EC types 10-13 (n=5; *P<0.05 versus corresponding specific organ and a minimum 4-fold difference and Log 2 probe intensity ≥6). D, mRNA expression determined by qRT-PCR of genes of the heart EC fingerprint in heart, pancreas, kidney or lung ECs relative to heart ECs (n=3-4; *P<0.05 versus heart ECs and a minimum 4-fold difference), revealing that most genes (81% compared to at least 2 of these tissues and 48% compared to all three tissues) were at least 4-fold enriched in heart ECs. ND: not detectable. Quantitative data represent mean ± s.e.m.
Supplementary Figure II.
Supplementary Figure II . Analysis of the heart EC fingerprint in freshly isolated and cultured human EC samples.
A, mRNA expression determined by qRT-PCR of genes of the heart EC fingerprint in human (h) heart, brain or liver ECs relative to human heart ECs (n=3-10; *P<0.05; # P<0.1 versus heart ECs), revealing that part of the signature is also enriched in human heart ECs versus brain and liver ECs. ND: not detectable. B, mRNA expression determined by qRT-PCR of genes of the heart EC fingerprint in cultured (passage 1-10) human (h) heart ECs relative to freshly isolated human heart ECs (n=3-10; *P<0.05; # P<0.1 versus freshly isolated heart ECs), revealing that the majority of the genes of the heart EC fingerprint is silenced at least 90%. Data represent mean ± s.e.m. Diagrams represent mRNA expression determined by qRT-PCR for 29 genes of the heart EC fingerprint in cultured human heart ECs overexpressing certain TF (combination)s relative to a 'Cherry' reporter control. Primers in the 3'UTR region were used to distinguish endogenous expression from that caused by lentiviral overexpression. Two of the 31 signature genes were not included, i.e., Klra9 MEOX2&UTR&  TCF15&UTR&  WT1&UTR&  PPARG&UTR&  EBF3&  LPL&  FABP9&  RBP7&  TIMP4&  ADAMTS9&  AKAP5&  AQP7&  ADH1&  MAP3K5&  NAV3&  ABLIM3&  EEPD1&  ZDHHC2&  C1QTNF9&  RTN1&  PRND&  H19&  KCNA5&  PMP2&  SLC28A2&  NTS&  PAPSS2&  HN1L&  MCTP1&   +&MEOX2+Tcf15&  +&EBF3& all experiments where PPARG was overexpressed, an agonist, rosiglitazone, was added at 10 µM).
When PPARG was overexpressed alone, we measured a strong upregulation of three genes, two known targets, RBP7 (14) and AQP7 (15) , and one novel target (FABP9). When PPARG was combined with
MEOX2+Tcf15, for multiple genes, a superior inductive effect was obtained compared to MEOX2&UTR&  TCF15&UTR&  WT1&UTR&  PPARG&UTR&  EBF3&  LPL&  FABP9&  RBP7&  TIMP4&  ADAMTS9&  AKAP5&  AQP7&  ADH1&  MAP3K5&  NAV3&  ABLIM3&  EEPD1&  ZDHHC2&  C1QTNF9&  RTN1&  PRND&  H19&  KCNA5&  PMP2&  SLC28A2&  NTS&  PAPSS2&  HN1L& Log 2 microarray probe set intensity for the most described membrane FA translocase/transporters revealing that CD36 is the FA translocase expressed at the highest level in freshly isolated murine heart ECs (n=5). Right: qRT-PCR copy number quantification relative to Gapdh confirming the microarray data on the left (n=4-7). Data represent mean ± s.e.m. 
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